Boehringer Ingelheim Animal Health
Global leader in Marek's disease vaccine production and the world's largest producer of poultry vaccines. Its Gainesville, Georgia facility produces approximately 60 billion poultry vaccine doses per year for the US and ~60 other countries — one of the largest single biological manufacturing sites in the world. In 2024, acquired Elanco's US poultry biologics portfolio for $885M, further consolidating leadership. Product portfolio includes HVT-based vaccines, PREVEXXION RN (chimeric Serotype 1, first new MDV1 innovation in 40+ years, approved EU/UK 2021), and the VAXXITEK recombinant HVT vector family. Also a major human pharmaceutical company (Jardiance, Pradaxa, Spiriva, Dupixent collaborator).